Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2011

Open Access 01-12-2011 | Case report

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report

Authors: Winnie WK Ng, Zenith HY Wu, Timothy YY Lai

Published in: Journal of Medical Case Reports | Issue 1/2011

Login to get access

Abstract

Introduction

Central serous chorioretinopathy is characterized by serous neurosensory detachment of the macula and it usually resolves spontaneously with good visual prognosis. In some patients, however, the serous retinal detachment might be very extensive and can result in bullous exudative retinal detachment. We evaluated the use of half-dose verteporfin photodynamic therapy for the treatment of bullous retinal detachment in idiopathic central serous chorioretinopathy.

Case presentation

We report the case of a 51-year-old Chinese man who presented with blurred vision in his right eye and superior visual field defect due to bullous variant of central serous chorioretinopathy. No improvement in vision and retinal detachment was noted after three months of observation and a short course of oral acetazolamide. He was then treated with half-dose verteporfin photodynamic therapy and his visual acuity improved from 20/70 to 20/25 within one month of treatment. Three months after photodynamic therapy, there was complete resolution of sub-retinal fluid and bullous retinal detachment. No recurrence of central serous chorioretinopathy was noted in three years of follow-up.

Conclusion

We report the beneficial effect of photodynamic therapy with half-dose verteporfin as a treatment option for bullous retinal detachment caused by central serous chorioretinopathy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Otsuka S, Ohba N, Nakao K: A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina. 2002, 22 (1): 25-32. 10.1097/00006982-200202000-00005.CrossRefPubMed Otsuka S, Ohba N, Nakao K: A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina. 2002, 22 (1): 25-32. 10.1097/00006982-200202000-00005.CrossRefPubMed
2.
go back to reference Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM, Aisman A: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003, 23 (3): 288-298. 10.1097/00006982-200306000-00002.CrossRefPubMed Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM, Aisman A: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003, 23 (3): 288-298. 10.1097/00006982-200306000-00002.CrossRefPubMed
3.
go back to reference Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS: Safety enhanced photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 2006, 90 (7): 869-874. 10.1136/bjo.2006.090282.CrossRefPubMedPubMedCentral Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS: Safety enhanced photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 2006, 90 (7): 869-874. 10.1136/bjo.2006.090282.CrossRefPubMedPubMedCentral
4.
go back to reference Shin JY, Woo SJ, Yu HG, Park KH: Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011, 31 (1): 119-126. 10.1097/IAE.0b013e3181e378f2.CrossRefPubMed Shin JY, Woo SJ, Yu HG, Park KH: Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011, 31 (1): 119-126. 10.1097/IAE.0b013e3181e378f2.CrossRefPubMed
5.
go back to reference Chan WM, Lai TY, Lai RY, Liu DT, Lam DS: Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008, 115 (10): 1756-1765. 10.1016/j.ophtha.2008.04.014.CrossRefPubMed Chan WM, Lai TY, Lai RY, Liu DT, Lam DS: Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008, 115 (10): 1756-1765. 10.1016/j.ophtha.2008.04.014.CrossRefPubMed
6.
go back to reference Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, Li XX: Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina. 2009, 29 (8): 1155-1161. 10.1097/IAE.0b013e3181a6c028.CrossRefPubMed Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, Li XX: Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina. 2009, 29 (8): 1155-1161. 10.1097/IAE.0b013e3181a6c028.CrossRefPubMed
Metadata
Title
Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
Authors
Winnie WK Ng
Zenith HY Wu
Timothy YY Lai
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2011
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-5-208

Other articles of this Issue 1/2011

Journal of Medical Case Reports 1/2011 Go to the issue